Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated)

References

• Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307–41
   PubMed Web of Science ®Google Scholar
• Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310–6
   PubMed Web of Science ®Google Scholar
• Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T-24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990; 265: 3189–92
   PubMed Web of Science ®Google Scholar
• Nathan CF. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon-gamma. Interferon 1986; 7: 125–43
   PubMedGoogle Scholar
• Reibnegger G, Aichberger C, Fuchs D, Hausen A, Spielberger M, Werner ER, et al. Post-transplant neopterin excretion in renal allograft recipients: a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991; 52: 58–63
   PubMed Web of Science ®Google Scholar
• Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993; 91: 207–13
   PubMedGoogle Scholar
• Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15: 483–90
   PubMedGoogle Scholar
• Brown AE, Herrington DA, Webster HK, Clyde DF, Sztein MB, Davis JR, et al. Urinary neopterin in volunteers experimentally infected with Plasmodium falciparum. Trans R Soc Trop Med Hyg 1992; 86: 134–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Jäger H, Popescu M, Reibnegger G, Werner ER, Dierich MP, et al. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990; 26: 75–9
   PubMed Web of Science ®Google Scholar
• Strohmaier W, Redl H, Schlag G, Inthorn D. D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med. 1987; 15: 757–60
   PubMed Web of Science ®Google Scholar
• Hensler T, Sauerland S, Lefering R, Nagelschmidt M, Bouillon B, Andermahr J, et al. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock 2003; 20: 420–6
   PubMed Web of Science ®Google Scholar
• Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235–43
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 341–8
   PubMed Web of Science ®Google Scholar
• Hughes M. Recombinant human activated protein C. Int J Antimicrob Agents 2006; 28: 90–4
   PubMedGoogle Scholar
• Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, et al. Treatment effects of Drotrecogin-alpha (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 1924–33
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, et al. PROWESS Sepsis Study Group. Drotrecogin-alpha (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642–53
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–55
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–29
   PubMed Web of Science ®Google Scholar
• Yan SC, Razzano P, Chao YB, Walls JD, Berg DT, McClure DB, et al. Characterization and novel purification of recombinant human protein C from 3 mammalian cell lines. Biotechnology (N Y) 1990; 8: 655–61
   PubMedGoogle Scholar
• Czeslick EG, Nestler F, Simm A, Struppert A, Sablotzki A. Drotrecogin-alpha (activated) does not affect intracellular production of interleukin-6 and tumour necrosis factor-alpha in endotoxin-stimulated human monocytes. Anesth Analg 2005; 101: 1805–8
   PubMedGoogle Scholar
• Brueckmann M, Hoffmann U, De Rossi L, Weiler HM, Liebe V, Lang S, et al. Activated protein C inhibits the release of macrophage inflammatory protein-1 from THP-1 cells and from human monocytes. Cytokine 2004; 26: 106–13
   PubMed Web of Science ®Google Scholar
• Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M, et al. Drotrecogin-alpha (activated) inhibits NF-kappa B activation and MIP-1 release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004; 53: 528–33
   PubMedGoogle Scholar
• Weiss G, Glaser K, Kronberger P, Ambach E, Fuchs D, Bodner E, et al. Distinct distributions of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation. Biol Chem Hoppe Seyler 1992; 373: 289–94
   PubMed Web of Science ®Google Scholar